BROWSERSTACK
14.12.2021 14:02:07 CET | Business Wire | Press release
BrowserStack , the world's leading software testing platform, today announced the acquisition of Nightwatch.js, the popular open-source test automation framework. BrowserStack will work with the Nightwatch team to make Nighwatch.js the de-facto choice for developers. Nightwatch.js will continue to remain open-source and free.
Nightwatch.js, the Node.js powered end-to-end test automation framework, is among the fastest-growing Selenium-based tools with 1 million monthly npm installs and over 10.5k GitHub stars. With its simple syntax and an in-built test runner, developers can run and manage tests without any hassle.
“Partnering with BrowserStack gives us the resources to build for the future and scale Nightwatch to greater heights,” said Andrei Rusu, Creator of Nighwatch.js. “Our focus will be to proactively engage with the community for feedback and roll out updates to improve the core experience for developers. We've already launched Nightwatch 2.0 in beta, and we're excited about the next chapter.”
Welcoming Nightwatch.js into its family of open-source collaborations, BrowserStack is doubling down on its support for the community and intends to scale such partnerships in the future. BrowserStack's Open Source Team actively participates and contributes to the open-source ecosystem. In addition, through its Open Source Program, BrowserStack has backed over 2,400 open source projects, enabling maintainers and contributors to test their software for free.
“When open-source wins, everyone wins. Many of BrowserStack's own products are built on open-source technologies, and we know first-hand their power to bring significant change,” said Nakul Aggarwal, Co-founder and CTO of BrowserStack. “With Nightwatch.js, we're taking another step towards our vision of becoming the testing infrastructure for the internet—through open and inclusive development.”
About BrowserStack
BrowserStack is the world's leading software testing platform powering over two million tests every day across 15 global data centers. They help Microsoft, Twitter, Barclays, Expedia, and over 50,000 customers deliver quality software at speed by moving testing to our Cloud. Their platform provides instant access to 2,500+ real mobile devices and browsers on a highly reliable cloud infrastructure that effortlessly scales as testing needs grow. With BrowserStack, Dev and QA teams can move fast while delivering an amazing experience for every customer.
Founded in 2011, BrowserStack is a privately held company backed by Accel with offices in San Francisco, Mumbai, and Dublin. For more information, visit https://www.browserstack.com or follow on Twitter @browserstack .
About Nightwatch.js
Nightwatch.js is an integrated, open-source end-to-end testing solution for web applications and websites written in Node.js. Released in 2014, their vision is to deliver a tool packed with everything developers need out of the box to ship bug-free software easily. For more details, visit https://nightwatchjs.org/ or follow on Twitter @nightwatchjs .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005737/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom